Loading ...
Sorry, an error occurred while loading the content.

More Info on Bexxar (from Sept 4, 1997)

Expand Messages
  • BEN HAINES
    More Info on Bexxar (from Sept 4, 1997) Company Press Release Coulter Pharmaceutical Begins Outpatient Treatment with Bexxar PALO ALTO, Calif.--(BW
    Message 1 of 1 , Oct 6, 1997
    • 0 Attachment
      More Info on Bexxar (from Sept 4, 1997)

      Company Press Release

      Coulter Pharmaceutical Begins Outpatient Treatment with Bexxar

      PALO ALTO, Calif.--(BW Healthwire)--Sept. 4, 1997--Coulter Pharmaceutical Inc. (NASDAQ:CLTR) today
      announced that Bexxar(TM) (its radiolabeled monoclonal antibody), under development for the treatment of
      non-Hodgkin's lymphoma, is being administered on an outpatient basis under newly-enacted Nuclear Regulatory
      Commission (NRC) Guidelines.

      The guidelines, which went into effect on May 29, 1997, allow for the treatment and release of patients who
      receive Bexxar, replacing a previous requirement for hospitalization following certain radiotherapies.

      ``Having Bexxar administered on an outpatient basis provides a significant commercialization advantage as it
      eliminates the expense of hospitalization as well as fulfills the patient's desire to go home following therapy,'' said
      Michael F. Bigham, president and chief executive officer of Coulter Pharmaceutical. ``The therapy is already being
      administered in a simple, two-step dosing regimen. It now offers the convenience of an outpatient treatment
      setting.''

      University of Michigan Comprehensive Cancer Center reported that it had begun treating patients with Bexxar on an
      outpatient basis. ``Our first patient was sent home immediately following Bexxar therapy,'' said Richard L. Wahl,
      M.D., professor of internal medicine and radiology at the University of Michigan. ``From our experience, Bexxar is
      easy to administer and well-tolerated by patients. Allowing patients to go home following this therapy is a significant
      added convenience.''

      Coulter Pharmaceutical also announced that the Bexxar manufacturing process has been successfully transferred
      to a central production facility. Previously, Coulter's unlabeled monoclonal antibody was shipped to clinical trial sites
      where the last step of radiolabeling was conducted.

      Nordion of Ontario, Canada, Coulter's contract manufacturing partner, is currently radiolabeling the product at its
      facility and then shipping Bexxar in ``ready-to-administer'' form to clinical trial sites across the United States. The
      new central production process was implemented to facilitate broad patient access to the therapy by providing for
      convenient administration.

      Bigham added, ``The treatment of patients on an outpatient basis and the availability of centrally-radiolabeled
      antibody are significant commercial milestones. We are very pleased with our pre-commercialization progress and
      expect these recent accomplishments to provide patients greater access to the therapy while streamlining costs for
      the provider.''

      Bexxar, which is an antibody radiolabeled with iodine- 131(I131), attaches to a protein found only on the surface of
      B-cells, both non-Hodgkin's lymphoma B-cells and some normal B-cells. Through this targeted approach, the tumor
      cells receive a greater concentration of the therapeutic radiation from Bexxar relative to normal tissues. The
      therapy is administered in a regimen consisting of two intravenous doses given about one week apart -- first an
      imaging dose and then a therapeutic dose.

      Coulter is evaluating Bexxar in a multicenter, pivotal Phase II/III clinical study in low-grade non-Hodgkin's patients
      who are refractory to chemotherapy. The company plans to complete enrollment in this trial as early as December
      1997 and expects to file a biologics license application (BLA) with the FDA in the second half of 1998.

      Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with
      cancer. The company currently is developing a family of cancer therapeutics based upon two platform
      technologies: conjugated antibodies and tumor-activated peptide (TAP) pro-drugs.

      The company's most advanced product candidate is Bexxar (previously referred to as the B-1 Therapy) for the
      treatment of non-Hodgkin's lymphoma. The company also is developing a TAP pro-drug version of doxorubicin to
      potentially treat certain solid tumor cancers.

      Except for the historical information contained herein, the matters discussed in this news release are
      forward-looking statements that involve risks and uncertainties, including uncertainties related to product
      development, uncertainties related to the need for regulatory and other government approvals, dependence on
      proprietary technology, uncertainty of market acceptance of Bexxar or the company's other product candidates
      and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. In
      particular, see ``Item 1. Financial Business-Risk Factors'' of the company's Form 10-K for the year ended December
      31, 1996.


      Contact:

      Coulter Pharmaceutical
      Sylvia Wheeler, 415/842-7306
    Your message has been successfully submitted and would be delivered to recipients shortly.